Trial reportBMC complementary and alternative medicine2016
Moxibustion treatment for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial.
Trial report in BMC complementary and alternative medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02421627 (Study on the Mechanism of Moxibustion Effect on Treating Diarrhea-predominant Irritable Bowel Syndrome), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study on the Mechanism of Moxibustion Effect on Treating Diarrhea-predominant Irritable Bowel Syndrome
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Efficacy and safety of Chinese botanical drug Si Shen Wan in irritable bowel syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- Clinical evidence of acupuncture and moxibustion for irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.Frontiers in public health · 2022Pooled it
- Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationTrial
- Electroacupuncture Alleviates Pulmonary and Intestinal Injury in Septic Mice via Inhibiting NLRP3 Inflammasome and Remodeling Gut Microbiota.Current medical science · 2026Article
- Comparison of acupuncture, moxibustion, and pharmacotherapy in improving diarrhea-predominant irritable bowel syndrome.Frontiers in microbiology · 2025Article
- Article
- Moxibustion treatment for Parkinson's disease: study protocol for a randomized controlled trial.BMC complementary medicine and therapies · 2023Article
- Article
- Effects of adherence to the Mediterranean diet in children and adolescents with irritable bowel syndrome.World journal of clinical pediatrics · 2022Article
- Research Trends of Moxibustion Therapy for Pain Treatment Over the Past Decade: A Bibliometric Analysis.Journal of pain research · 2022Review
- Long-term effect of moxibustion on irritable bowel syndrome with diarrhea: a randomized clinical trial.Therapeutic advances in gastroenterology · 2022Article
- Full-Length Transcriptome Analysis Reveals Candidate Genes Involved in Terpenoid Biosynthesis inFrontiers in genetics · 2021Article
- Effect of mild moxibustion on intestinal microbiota and NLRP6 inflammasome signaling in rats with post-inflammatory irritable bowel syndrome.World journal of gastroenterology · 2019Article
- Metabolomics analysis of herb-partitioned moxibustion treatment on rats with diarrhea-predominant irritable bowel syndrome.Chinese medicine · 2019Article
- Effect of Different Dosages of ST36 Indirect Moxibustion on the Skin Temperature of the Lower Legs and Feet.Medicines (Basel, Switzerland) · 2018Article
- De novo assembly and analysis of the Artemisia argyi transcriptome and identification of genes involved in terpenoid biosynthesis.Scientific reports · 2018Article
- Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome.World journal of gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrritable bowel syndrome (IBS) is a worldwide disease with high morbidity. The effect of current treatment with Western medicine is not satisfactory. Although moxibustion treatment is widely used for gastrointestinal diseases, randomized controlled trials on the use of this treatment for IBS are limited. This study aims to evaluate the clinical efficacy and safety of moxibustion treatment in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). METHODS/
designA multi-center, randomized, single-blind and placebo-controlled trial is employed. 104 cases will be divided into two groups: (1) a mild-warm moxibustion group in which moxa stick is 3-5 cm away from acupuncture points and the skin temperature is maintained at 43 ± 1 °C; and (2) a placebo moxibustion group in which moxa stick is 8-10 cm away from acupuncture points and the skin temperature is maintained at 37 ± 1 °C. Moxibustion is performed on bilateral ST25 and ST36 in the two groups for 30 min each time, three times a week for 6 weeks. The patients are followed up at the 12th and 18th weeks. Adequate relief is used as a primary outcome measure; IBS symptom severity score, Bristol stool form scale, IBS quality-of-life questionnaire, and hospital anxiety and depression scale are used as secondary outcome measures. DISCUSSION: This study aims to demonstrate the safety and efficacy of moxibustion treatment for IBS-D, which may validate moxibustion as an effective therapy for treating IBS-D.
trial registrationClinicalTrials.gov identifier NCT02421627 (8 April 2015).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.